In 2017, the FDA approved tisagenlecleucel (a CD19-specific 4-1BB-CAR construct) for the treatment of relapsed or refractory B-ALL, and in 2018, the FDA approved axicabtagene ciloleucel (a CD19-specific CD28-CAR construct) for the treatment of relapsed or refractory DLBCL. Here, CD19 is linked to diffuse large B-cell lymphoma.